- Home
- VRTS vs ETNB Comparison
VRTS vs ETNB Comparison
Compare VRTS & ETNB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VRTS
- ETNB
- Stock Information
- Founded
- VRTS 1988
- ETNB 2018
- Country
- VRTS United States
- ETNB United States
- Employees
- VRTS N/A
- ETNB N/A
- Industry
- VRTS Investment Managers
- ETNB Biotechnology: Pharmaceutical Preparations
- Sector
- VRTS Finance
- ETNB Health Care
- Exchange
- VRTS Nasdaq
- ETNB Nasdaq
- Market Cap
- VRTS 1.0B
- ETNB 1.0B
- IPO Year
- VRTS 1992
- ETNB 2019
- Fundamental
- Price
- VRTS $170.76
- ETNB $10.10
- Analyst Decision
- VRTS Hold
- ETNB Strong Buy
- Analyst Count
- VRTS 4
- ETNB 8
- Target Price
- VRTS $167.75
- ETNB $26.43
- AVG Volume (30 Days)
- VRTS 52.2K
- ETNB 2.1M
- Earning Date
- VRTS 07-25-2025
- ETNB 05-01-2025
- Dividend Yield
- VRTS 5.27%
- ETNB N/A
- EPS Growth
- VRTS 1.50
- ETNB N/A
- EPS
- VRTS 16.84
- ETNB N/A
- Revenue
- VRTS $902,839,000.00
- ETNB N/A
- Revenue This Year
- VRTS N/A
- ETNB N/A
- Revenue Next Year
- VRTS N/A
- ETNB N/A
- P/E Ratio
- VRTS $10.13
- ETNB N/A
- Revenue Growth
- VRTS 3.84
- ETNB N/A
- 52 Week Low
- VRTS $142.18
- ETNB $4.16
- 52 Week High
- VRTS $252.82
- ETNB $11.84
- Technical
- Relative Strength Index (RSI)
- VRTS 54.20
- ETNB 61.20
- Support Level
- VRTS $165.47
- ETNB $8.94
- Resistance Level
- VRTS $173.16
- ETNB $9.89
- Average True Range (ATR)
- VRTS 3.63
- ETNB 0.68
- MACD
- VRTS -0.30
- ETNB 0.11
- Stochastic Oscillator
- VRTS 36.21
- ETNB 71.75
About VRTS Virtus Investment Partners Inc.
Virtus Investment Partners Inc provides investment management and related services to institutions and individuals. It uses a multi-manager, multi-style approach, offering investment strategies from investment managers, each having its distinct investment style, autonomous investment process, and individual brand, as well as from select unaffiliated managers for certain funds. Through its multi-manager model, the group provides investment managers with distribution, business, and operational support. The Company operates in one business segment, namely as an asset manager providing investment management and related services for individual and institutional clients.
About ETNB 89bio Inc.
89bio Inc is a United States-based clinical-stage biopharmaceutical company focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its product candidate, pegozafermin (previously BIO89-100), a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is currently being developed for the treatment of nonalcoholic steatohepatitis (NASH) and for the treatment of severe hypertriglyceridemia (SHTG).